Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 [R 788, fostamatinib] in Patients With Rheumatoid Arthritis Who Have Failed at Least One Biologic

Next Previous
Trial Profile

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 [R 788, fostamatinib] in Patients With Rheumatoid Arthritis Who Have Failed at Least One Biologic

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fostamatinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms TASKI-3
  • Sponsors Rigel Pharmaceuticals

    • Most Recent Events

    • 24 Mar 2012 This trial is recruiting in France.
    • 01 Feb 2011 Results published in the Arthritis and Rheumatism.
    • 21 Oct 2009 Results were reported at the 73rd Annual Scientific Meeting of the American College of Rheumatology and the 44th Annual Meeting of the Association of Rheumatology Health Professionals.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top